# Lenalidomide Plus Bendamustine and Rituximab for Untreated CLL/SLL

> **NCT01400685** · PHASE1 · COMPLETED · sponsor: **Massachusetts General Hospital** · enrollment: 34 (estimated)

## Conditions studied

- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- B Chronic Lymphocytic Leukemia

## Interventions

- **DRUG:** Lenalidomide
- **DRUG:** Bendamustine
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT01400685
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-12
- **Primary completion:** 2017-12
- **Final completion:** 2018-01
- **Target enrollment:** 34 (ESTIMATED)
- **Last updated:** 2018-01-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01400685

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01400685, "Lenalidomide Plus Bendamustine and Rituximab for Untreated CLL/SLL". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT01400685. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*